Every 10-Q that BEONE MEDICINES LTD (BEIGF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BEIGF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEIGF filings page.
BeOne Medicines Ltd. reported strong results for the quarter ended June 30, 2026, with total revenues of $1,705,071 (amounts in thousands of $), up 29.6% from $1,315,300 a year earlier. Net income rose to $237,007 from $94,320, and diluted earnings per share were $0.16, or $2.05 per ADS.
Growth was driven mainly by oncology portfolio expansion: BRUKINSA® net product revenue increased 31.4% to $1,247,640, TEVIMBRA® grew 18.1% to $228,515, and Amgen‑in‑licensed products such as XGEVA® and BLINCYTO® also posted double‑digit gains. Overall net product revenue rose 29.0% to $1,679,794, while other revenue nearly doubled to $25,277.
Gross profit improved to $1,530,541, reflecting an 89.6% product gross margin. Research and development expense grew 16.6% to $612,280 and selling, general and administrative expense rose 10.3% to $593,214 as the company invested in its pipeline and global commercialization. Cash and cash equivalents were $5,098,041 at June 30, 2026, alongside $882,163 of long‑term debt, $190,896 of short‑term debt, and a $906,313 sale‑of‑future‑royalty liability.
BeOne Medicines Ltd. reported Q1 2026 revenue of $1.51B, up 35.5% from a year earlier, driven mainly by strong growth in BRUKINSA and TEVIMBRA. Net income rose sharply to $227.4M, compared with near breakeven a year ago, as higher sales and improved gross margin outpaced increased R&D and commercial spending.
Product revenue reached $1.49B, led by BRUKINSA at $1.09B (up 38.3%) and steady growth in Amgen-partnered products. Gross margin improved to 88.8% on a richer mix of BRUKINSA and efficiency gains. Operating cash flow climbed to $201.3M, lifting cash, cash equivalents and restricted cash to $4.85B, while total debt stood at $1.08B and the IMDELLTRA royalty financing liability at $904.4M.
BeOne Medicines Ltd. (ONC) reported a profitable Q3. Total revenues were $1,412,284 for the three months ended September 30, 2025, driven by product revenue of $1,395,013. Net income was $124,841, a clear turnaround from a loss a year ago, as gross profit rose to $1,215,774 and operating income reached $163,114.
Cash generation was strong with year‑to‑date operating cash flow of $710,233, lifting cash and cash equivalents to $4,036,868. The company monetized future IMDELLTRA royalties, receiving $885,000 upfront from Royalty Pharma, recorded as a royalty sale liability with a 6.4% effective annual rate. BRUKINSA led product sales at $1,040,691 in the quarter, followed by TEVIMBRA at $190,623. Short‑term debt stood at $813,296 and long‑term debt at $139,571. Shares outstanding were 1,438,553,263 as of November 1, 2025.